Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML)-Reference-Cited by-同舟云学术

Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML)

Published:2021-04 Issue: Volume:897 Page:173944
ISSN:0014-2999
Container-title:European Journal of Pharmacology
language:en
Short-container-title:European Journal of Pharmacology

Author:

Lu Tingting,Cao Jiangyan,Zou Fengming,Li Xixiang,Wang Aoli,Wang Wenliang,Liang Huamin,Liu Qingwang,Hu Chen,Chen Cheng,Hu Zhenquan,Wang Wenchao,Li Lili,Ge Jian,Shen Yang,Ren Tao,Liu Jing^ORCID,Xia Ruixiang,Liu Qingsong

Funder

Doctoral Program Foundation of Institutions of Higher Education of China

China Postdoctoral Science Foundation

Hefei Institutes of Physical Science

Chinese Academy of Sciences

Anhui Provincial Natural Science Foundation

Anhui Province Excellent Young Talents Fund Program of Higher Education Institutions

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Pharmacology

Reference33 articles.

1. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review;An;Leuk. Res.,2010

2. Chronic myeloid leukemia;Apperley;Lancet,2015

3. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia;Arber;Blood,2016

4. Experimental and integrative analyses identify an ETS1 network downstream of BCR-ABL in chronic myeloid leukemia (CML);Desterke;Exp. Hematol.,2018

5. The BCR-ABL inhibitor nilotinib influences phenotype and function of monocyte-derived human dendritic cells;Dorfel;Cancer Immunol. Immunother.,2018

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synergistic Inhibitory Effect of Berberine and Low-Temperature Plasma on Non-Small-Cell Lung Cancer Cells via PI3K-AKT-Driven Signaling Axis;Molecules;2023-11-27

2. The Progress of Small Molecule Targeting BCR-ABL in the Treatment of Chronic Myeloid Leukemia;Mini-Reviews in Medicinal Chemistry;2023-10-06

3. Small-molecule LRRK2 inhibitors for PD therapy: Current achievements and future perspectives;European Journal of Medicinal Chemistry;2023-08

4. Determination and measurement of Imatinib by a fluorescence quenching sensor based on halloysite nanotubes modified by zirconium metal organic framework;Materials Chemistry and Physics;2023-02

5. Design, synthesis, and biological evaluation of trizole-based heteroaromatic derivatives as Bcr-Abl kinase inhibitors;European Journal of Medicinal Chemistry;2022-08